SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

The centenary of insulin discovery represents an important opportunity to transform diabetes
from a fatal diagnosis into a medically manageable chronic condition. Insulin is a key …

Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …

The prevalence of heart failure is on the rise and imposes a major health threat, in part, due
to the rapidly increased prevalence of overweight and obesity. To this point …

Objectives The goal of this study was to evaluate the effect of empagliflozin, in addition to
optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis …

Aims/hypothesis: SGLT-2 inhibitors (SGLT-2i) have been studied as potential treatments
against NAFLD, showing varying beneficial effects. The molecular mechanisms mediating …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Obesity-associated inflammation is a systemic process that affects all metabolic organs.
Prominent among these is adipose tissue, where cells of the innate and adaptive immune …